Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jeff, I think by the end of the day we will see a lot more volume....and after hours. We are looking at a one two punch with the multi-gene data tomorrow also. The analyst mention of BDT designation is a nice plus and testimony to the importance of the data being presented.
The new Oncosec CEO said this morning that the recent Oncosec data was the reason for joining the company. Very positive conference call this morning. The ducks are lining up in a row for Oncosec now.
Nice...I think we will start to see some price target upgrades and hopefully new analysts starting coverage on Oncosec after SITC.
Wishful thinking. Just waiting for this to explode. It will happen soon.
The stock ticker on my computer is showing Oncosec up by 70% right now....that has to be a gliche.
Just found it in the pr:
"The updated data will be presented in an oral poster presentation (P524) by Dr. Alain Alagzi at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD on November 10th, 2017 at 12:45 p.m. EST."
Jeff, is the combo study data presentation this afternoon and the multi-gene data presentation tomorrow? I think I got the dates confused. Nice they did a conference/analyst call this morning. Not sure why Adam F. didn't wait to write his article until after the actual presentations at SITC. I think there is more detailed data to be revealed. Waiting with anticipation. Good times ahead.
Thanks for sharing Bro.
Oddly their share prices are exactly the same today but Idera market cap is over 300 mil. Seems Oncosec is way undervalued if you compared the two.
Do you have comparable data on that?
Anybody know how Oncosec stacks up against Idera Pharmaceuticals melanoma data?
Wikipedia states: "An institutional investor is an entity which pools money to purchase securities, real property, and other investment assets or originate loans. Institutional investors include banks, insurance companies, pensions, hedge funds, REITs, investment advisors, endowments, and mutual funds."
Anybody know what market cap Oncosec would need to be listed on the Russell US Equity Indexes?
I hope all of us LONGS here make that kind of wealth with Oncosec...I do believe it is a real possibility now. The fact that millions of people love to bake their skin while sitting on boats and beaches is exactly why Oncosec will rule the melanoma market. A yacht and Island would be nice and I would stay covered from the sun for sure.
Six degrees of separation. I have been in Merck for years and watched these things happen. Merck/Medco....value creation. Oncosec shares for Merck.....Merck spinout of animal health business eventually to focus on Keytruda combo's.....means more Merck shares and possibly a stake in another spinoff. Longer term value creation. LOVE IT! I just imagine converting $200,000 of Oncosec shares at least into Merck shares and I would be very happy with that.
Hold on to your share people....looks like we just shot up to 2.10.....going higher here. Love it!
When Merck takeover of Oncosec happens I wouldn't mind a swap for Merck shares since Merck has pulled back 20% recently. That would be another way to squeeze more value out of Oncosec shares. Merck is a much safer long term holding that will go up with a buyout of Oncosec. Merck is a good long term value play. They need to buy more innovation and Oncosec has that in spades.
They can shake all they want. I'm not budging. This will rocket higher for sure.
I totally agree with you on that, I just don't trust the market enough to believe retail investors won't get screwed waiting forever for that to happen. Oncosec with an expanded pipeline like Biomarin in orphan drug indications could have a $100 share price. I do believe that, but I really think Oncosec will get a buyout way before that would happen.
Punit and Slansky have said in the past 2 years that Oncosec is set up for an exit opportunity. Now that Punit has stepped aside as CEO, I think that is the writing on the wall, he is ready to move on when Oncosec is taken out by.....of course....Merck.
I agree. Merck might be willing to take the leap with a buyout of Oncosec before PISCES data release to ensure nobody else can get it later. Look at Amgen paying 1 Billion to get T-Vec from Biovet. That was 2011. They paid up way in advance. Sometimes it is worth the risk to big pharma.....which would be the case with Oncosec.....too much to lose playing second fiddle to anybody else.
Oncosec clearly has the edge over Incyte. Incyte has a 22 billion market cap...Oncosec is the company on sale here. I wouldn't settle for anything less than $20 or $30 a share. Been here long enough not to get scared out of my shares. LONGS DESERVE THIS!
ADX trend strength indicator is just under 50 for Oncosec. A move above 50 will confirm a very strong trend. RSI is 80.70
Barchart.com 100% BUY RATING ON ONCOSEC.....strongest rating for Oncosec I have seen in years.
https://www.barchart.com/stocks/quotes/ONCS/opinion
New Oncosec Holdings updates will trickle in now. Here is a new one for today:
ZURCHER KANTONALBANK (ZURICH CANTONALBANK) now owns 92,100 shares of Oncosec.
$oncs confirmed with IR that there will be more information at the oral SITC presentation on Friday according to a poster on twitter.
"please note that the oral poster presentation on Nov 10th will include detailed patient data, as well as additional immune monitoring/biomarker data that was not described in the PR. Additionally, the poster is a robust overview of the patient population, prior treatment and current status as of the last data cutoff." best, Angelita
In all my years holding Oncosec, I think this is the one time they got it all right with timing news and capital raise and came out on top of things. Punit would not have stepped aside as CEO unless he believed that it was necessary to ensure Oncosec's success. I do think the CEO change was timed and after SITC I think Dan will get a lot more people on board here.
We are just getting started. The real move hasn't even begun yet. We are going much higher and people will be kicking themselves because they didn't buy at $2 because they thought it would drop back to $1.
Oncosec is in fine shape for the next year regarding finances. I wouldn't be surprised if the new CEO scores licensing deals even before PISCES data is released.....and I mean that in a general sense meaning other companies besides Merck for use in other indications. Other companies may be looking at Oncosec now with this type of excitement going on.
BAR CHART READING IS 100% STRONG BUY....HIGHEST RATING FOR ONCOSEC
https://www.barchart.com/stocks/quotes/ONCS/opinion
The takeaway from the Adam F. article is: good PISCES results for Oncosec will override the INCYTE results because Oncosec PISCES trial is targeting the checkpoint failure population....more conclusive data. Good results from PISCES and we will see an INCYTE type of valuation next year. LOOKING GOOD!
Adam F. says Oncosec data is on par with INCYTE data for comparison. INCYTE is a 22 Billion dollar company....WOW! We got a lot of room to run!
100% DOR (duration of response).....NIIIIICCCEEE!
I think we get a nice reaction to this CEO appointment news tomorrow. Delayed reaction right now. This is BIGLY.
The market will respond very favorably to this. I recently tweeted Brad Loncar if he had Oncosec on his radar....no response. Today with this announcement, Brad Loncar just tweeted "Dan is an incredibly nice guy. Happy to see this." Oncosec is definitely on the radar and will be added to many more funds. I am anxious to see the release of any more SEC filings of ownership. Certainly more funds have been quietly adding with the increase in daily trading volume this past month.
This is big news for Oncosec and a good sign for the upcoming year as they move forward with PISCES. I now think there should be no doubt in anybody's mind that they are positioning for a buyout with the PISCES data next year. Oncosec is extremely confident they will get an FDA accelerated approval. Punit stepping aside right now is the sign he is willing to make a deal and move on. Shareholders will reap $$$.
That is good to know. I would hope they have no more financial obligations to Inovio.
The mention of personalized tumor vaccines did catch my eye. Merck is heavily involved in vaccines and would be very interested in this. The mention of vaccines had me thinking about Inovio. They are involved in vaccines and electroporation. I think in the future all 3 of these companies will be more linked together in some way. I think Oncosec still has a tie to Invoio regarding licensing fees for commercialized products.
Just speculation on my part but if Oncosec owed royalties to Inovio for any commercialized products using electroporation it might be in their best interest in pursuing a sale of the company after an FDA approval for immunopulse. I hope that is what happens. Inovio can get royalty money from Merck instead.
hschlauch, what is your initial response to the multi-gene abstract? Anything really jump out at you. It is above my head to understand the science lingo.
Alot of patients could be treated opening up a huge market for Oncosec and Merck. Orphan drug status comes with price incentives too and market exclusivity for 7 years. Those two factors alone are underestimated also. Sometimes the hare wins the race. Oncosec is about to turn on the jets going into next years data release with PISCES trial.
Amgen paid 1 billion to get their hands on T-Vec for melanoma. It is fair to say that Oncosec would fetch a similar price if Merck wants ep-il12 bad enough.
Market is still leary and I still don't understand why the market underestimates Punit's ability to land a big deal for Oncosec. He did it with Inovio...scoring a deal with Roche. He will do it again with Oncosec.
Absolutely agree with that Titan. The risk is high but so is the reward. Waiting for trial results takes patience, but worth the wait if this works out. The multi-gene opportunity will be the icing on the cake....for Merck....if they acquire Oncosec.